Bausch + Lomb Corporation (TSX:BLCO)
24.74
+0.37 (1.52%)
Oct 9, 2026, 3:58 PM EST
Bausch + Lomb Revenue
Bausch + Lomb had revenue of $1.39B USD in the quarter ending June 30, 2026, with 9.08% growth. This brings the company's revenue in the last twelve months to $6.00B, up 9.28% year-over-year. In the year 2025, Bausch + Lomb had annual revenue of $5.10B with 6.47% growth.
Revenue (ttm)
$6.00B
Revenue Growth
+9.28%
P/S Ratio
1.17
Revenue / Employee
$461.89K
Employees
13,000
Market Cap
8.82B CAD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.10B | 310.00M | 6.47% |
| Dec 31, 2024 | 4.79B | 645.00M | 15.56% |
| Dec 31, 2023 | 4.15B | 378.00M | 10.03% |
| Dec 31, 2022 | 3.77B | 3.00M | 0.08% |
| Dec 31, 2021 | 3.77B | 353.00M | 10.35% |
| Dec 31, 2020 | 3.41B | -366.00M | -9.69% |
| Dec 31, 2019 | 3.78B | 113.00M | 3.08% |
| Dec 31, 2018 | 3.67B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Apotex Health | 3.20B |
| Extendicare | 1.98B |
| Curaleaf Holdings | 1.87B |
| Green Thumb Industries | 1.72B |
| WELL Health Technologies | 1.52B |
| Sienna Senior Living | 1.08B |
| Knight Therapeutics | 547.31M |
| DRI Healthcare Trust | 285.04M |
Bausch + Lomb News
- 4 days ago - Bausch + Lomb advances oral treatment for dry AMD after FDA meeting - TheFly
- 4 days ago - Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting - Business Wire
- 4 days ago - Bausch + Lomb initiated with an Overweight at Barclays - TheFly
- 5 days ago - Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28 - Business Wire
- 4 weeks ago - Bausch + Lomb announces European CE Mark approval of SeeLyra - TheFly
- 4 weeks ago - Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser - Business Wire
- 4 weeks ago - Leerink bullish on Bausch + Lomb, initiates with an Outperform - TheFly
- 4 weeks ago - Bausch + Lomb initiated with an Outperform at Leerink - TheFly